How we run ourselves

The Royal Marsden is managed by a Board of Directors made up of a Chairman, Chief Executive, four other Executive Directors, and six non-Executive Directors

Our Board

The Board is satisfied that its current composition and balance between skills, knowledge and experience is complete and appropriate to the requirements of the Trust. 

The day-to-day running of the hospital is carried out by the Leadership Team made up of the Chief Executive, four Executive Directors, and the other members listed below.

Board meeting papers can be downloaded below. Please contact the Corporate Governance office on 020 811 8558 or email foundation.trust@rmh.nhs.uk if you would like to request previous meeting papers.

Mr Charles Alexander
Chairman
R/QAR

Charles Alexander was appointed as Chairman in December 2016. Charles’ experience at board level varies across the banking, industry and charitable sectors, including companies such as NM Rothschild, and GE Capital Europe. He is currently a Non-Executive Director of the Department of Culture, Media and Sport, and chairs The Countess of Munster Musical Trust as well as the musical charity Opera Rara. Charles Alexander currently also serves as Chairman of the Board of Trustees of The Royal Marsden Cancer Charity.

Executive Directors

Miss Cally Palmer CBE
Chief Executive 
QAR/ICR

Cally Palmer became Chief Executive of The Royal Marsden in 1998. She is also a Trustee of the ICR and a Trustee of The Royal Marsden Cancer Charity. She holds an MSc in Management from the London Business School, which she gained with distinction in 1995, and is a member of the Institute of Health Services Management.

Cally was awarded a CBE in 2006 for her contribution to the NHS. Cally was appointed as National Cancer Director for NHS England in 2015 and holds this position alongside her role as Chief Executive of The Royal Marsden. 

Mr Karl Munslow Ong
Chief Operating Officer 
QAR

Karl Munslow Ong joined The Royal Marsden in November 2018 as the Chief Operating Officer. Before taking on the role, Karl was the Deputy Chief Executive at Chelsea and Westminster NHS Foundation Trust, having joined as their Chief Operating Officer in March 2015, also working with The Royal Marsden through the Fulham Road Collaborative, Sphere and RM Partners. Karl started his career as a management consultant for PriceWaterhouseCoopers before moving to work at a strategic health authority. He was previously Chief Operating Officer at Hillingdon Hospital and has extensive operational management experience across a number of other acute trusts in London.

Dr Nicholas van As
Medical Director
QAR

Dr Nicholas van As was appointed Medical Director in January 2016. He has been a Consultant Clinical Oncologist in the Urology Unit at The Royal Marsden since 2008 and is the hospital’s Clinical Lead for stereotactic body radiotherapy (SBRT) and CyberKnife. Dr van As is also Co-Chair of the UK SBRT Consortium and the national clinical lead for NHS England’s Commissioning through Evaluation Programme for SBRT. His main research interests are in stereotactic and image-guided radiotherapy, risk prediction in early prostate cancer, and functional MRI, and he has published numerous papers on these subjects and delivered presentations at international meetings. He is the Chief Investigator for the PACE trial – an international, randomised controlled trial comparing SBRT to image-guided radiotherapy (IGRT) and surgery for treating prostate cancer. 

Mr Eamonn Sullivan
Chief Nurse 
A/QAR

Mr Eamonn Sullivan was appointed to the role of Chief Nurse at The Royal Marsden NHS Foundation Trust in January 2017. Previously he was Deputy Chief Nurse at University College London Hospitals and Deputy Chief Nurse at Guy’s and St Thomas’ NHS Foundation Trust, where he has also held positions as Head of Performance for Clinical Services and Head of Nursing for Surgery. Eamonn has an MSc in Health Service Development (Critical Care) from King’s College London, he is a Florence Nightingale Leadership Scholar, and has served in Iraq and Afghanistan in the Army Medical Services Reserves.

Mr Marcus Thorman
Chief Financial Officer 
A/QAR

Marcus Thorman joined The Royal Marsden as Chief Financial Officer in January 2015 from Imperial College Healthcare NHS Trust. Since joining the NHS through the graduate financial management training scheme, he has worked in several provider trusts including mental health and community, acute, teaching and specialist. Marcus has been involved in merging two trusts, private finance initiative (PFI) schemes and running a financial shared service for a number of NHS organisations. At Kettering General Hospital he was Deputy Director of Finance before taking on his first role as a Finance Director overseeing the process for delivering foundation trust status in 2008. During his time at Imperial College Healthcare NHS Trust, he led the finance team in delivering one of the largest financial turnarounds in the NHS; taking the Trust from a planned deficit to a surplus in two financial years. For seven months he was acting Chief Financial Officer while a new Chief Executive was being appointed.

Non-executive directors

Mr Ian Farmer*
A/R

Ian Farmer joined The Royal Marsden as a Non-Executive Director and Chair of the Audit and Finance Committee on 1 April 2014. Ian is a Chartered Accountant and former Chief Executive Officer of Lonmin Plc, the world’s third largest Platinum Group Metals (PGM) mining company.

Professor Paul Workman PhD DSc FMedSci FRSC
Chief Executive and President of the ICR 
QAR/ICR

Paul is also Harrap Professor of Pharmacology at ICR and was previously Head of  ICR’s Division of Cancer Therapeutics and Director if its CRUK Cancer Therapeutics Unit. He is Director of the CRUK ICR/Imperial  Convergence Science Centre. Paul has 40 years of experience in cancer research, including periods at Cambridge University (MRC Clinical Oncology Unit), Glasgow University (CRC/CRUK Beaton Laboratories) and AstraZeneca. Paul is internationally recognised for research in cancer drug discovery and chemical biology, with honours including election as a Fellow of the Royal Society and Fellow of the Academy of Medical Sciences. He is a Non-Exective Director of STORM Therapeutics and a member of the Board of Directors of the non-profit Chemical Probes Portal.

Mr Mark Aedy*
Senior Independent Director 
A/R

Mark Aedy joined The Royal Marsden as a Non-Executive Director in April 2016. He has 40 years’ experience in the financial services sector, building and managing investment banking franchises in the UK and internationally. At present, he is a Managing Director and Head of EMEA and Asia Investment Banking at Moelis & Company, a global independent investment bank, and is on its management committee. Prior to Moelis & Company, he worked at Bank of America Merrill Lynch serving on the Global Corporate and Investment Banking Executive Committee and at Merrill Lynch, where he was Head of Investment Banking, EMEA. He is a Trustee of The HALO Trust.

Ms Heather Lawrence OBE*
A/QAR

Heather Lawrence is an accomplished former Chief Executive with a track record of service quality improvement. Her last Chief Executive position was at Chelsea and Westminster NHS Foundation Trust from 2000 to 2012. Since 2012, she has held a number of NED positions and currently serves as Non-Executive Chair of the London Ambulance Service, which has been successfully brought out of special measures. She is a nurse by background and has an impressive track record of success in both her Executive and NED roles. Ms Lawrence brings her patient-focused clinical expertise to the role of the Non-Executive Director.

Professor Martin Elliott*
QAR

Professor Elliott is a Paediatric Cardiothoracic Surgeon who has spent the majority of his career at Great Ormond Street Hospital, where he held several clinical leadership positions including co-Medical Director from 2010 to 2015. He also holds a Chair in Paediatric Cardiothoracic Surgery at University College London, and is the 37th Professor of Physics at Gresham College. He is an established clinical leader with a strong understanding of the particular challenges and opportunities facing specialist trusts. As Co-Medical Director, Professor Elliott led on quality and safety, digital technology and clinical strategy development.

Mr William Jackson*


William Jackson is a Chief Executive and a founding partner of Bridgepoint, a leading international private equity group. In 2015, Bridgepoint owned businesses, operating across a range of sectors (including consumer, healthcare and media), generated combined revenues of €8.7 billion and EBITDA of €1.5 billion. William’s NED portfolio includes Chairman of the Board at Pret a Manger (2012 to 2018), NED at British Land Plc (2011 to present) and President of the Board Dorna Sports SA/MotoGP. 

Mr Christopher Clark*
A

Chris Clark is a Non-Executive Director of Aviva’s UKD digital legal entity and chairs their Conduct Committee. He is also an adviser to a number of Private Equity houses specialising in Marketing Services. In his corporate career, Chris was at HSBC between 2001 and 2017, and was Global Head of Marketing (2010–2017), reporting to the Group Chief Executive Officer. He was a member of the HSBC Group Management Board and Group Risk Management Committee. Prior to HSBC, Chris spent his career in the advertising and marketing services business, with time at Saatchi and Saatchi and also a four-year period in New York.

*The Non-Executive Directors which the Board considers to be independent.

Key

R
Member of Remuneration Committee


Member of Audit and Finance Committee

QAR
Member of Quality, Assurance and Risk Committee

ICR 
Member of the Board of Trustees of The Institute of Cancer Research

Other members of the Leadership Team

Pictured (left to right):

1st row: Karl Munslow Ong, Chief Operating Officer, Eamonn Sullivan, Chief Nurse, Cally Palmer CBEChief Executive, Marcus Thorman, Chief Financial Officer, Dr Nicholas van As, Medical Director, 

2nd row: Rachael Reeve, Director of Marketing and Communications, Nicky Browne, Director of Transformation and Charity Liaison, Antonia Dalmahoy, Managing Director of The Royal Marsden Cancer Charity, Lisa Emery, Chief Information Officer

3rd row: Sunil Vyas, Director of Projects and Estates, Dr Susan Lalondrelle, Lead for Clinical Oncology, Nicola Hunt, Managing Director of RM Partners, Jon Spencer, Divisional Director of Clinical Services

4th row: Nina Singh, Director of Workforce, Steven Francis, Director of Performance and Information, Professor David Nicol, Chief of Surgery, Shams Maladwala, Managing Director of Private Care
 

Not Pictured:

Professor David Cunningham, Director of Clinical Research
Ellie Bateman, Divisional Director, Cancer Services
Mr Thomas Ind, Divisional Medical Director, Private Care

 

Board and Leadership Team Register of Interests